Cargando…

Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults

BACKGROUND: Adults with certain comorbid conditions have a higher risk of pneumonia than the overall population. If treatment of pneumonia is more costly in certain predictable situations, this would affect the value proposition of populations for pneumonia prevention. We estimate the economic impac...

Descripción completa

Detalles Bibliográficos
Autores principales: Polsky, Daniel, Bonafede, Machaon, Suaya, Jose A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585380/
https://www.ncbi.nlm.nih.gov/pubmed/23113880
http://dx.doi.org/10.1186/1472-6963-12-379
_version_ 1782261160004812800
author Polsky, Daniel
Bonafede, Machaon
Suaya, Jose A
author_facet Polsky, Daniel
Bonafede, Machaon
Suaya, Jose A
author_sort Polsky, Daniel
collection PubMed
description BACKGROUND: Adults with certain comorbid conditions have a higher risk of pneumonia than the overall population. If treatment of pneumonia is more costly in certain predictable situations, this would affect the value proposition of populations for pneumonia prevention. We estimate the economic impact of community-acquired pneumonia (CAP) for adults with asthma, diabetes, chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) in a large U.S. commercially-insured working age population. METHODS: Data sources consisted of 2003 through 2007 Thomson Reuters MarketScan Commercial Claims and Encounters and Thomson Reuters Health Productivity and Management (HPM) databases. Pneumonia episodes and selected comorbidities were identified by ICD-9-CM diagnosis codes. By propensity score matching, controls were identified for pneumonia patients. Excess direct medical costs and excess productivity cost were estimated by generalized linear models (GLM). RESULTS: We identified 402,831 patients with CAP between 2003 through 2007, with 25,560, 32,677, 16,343, and 5,062 episodes occurring in patients with asthma, diabetes, COPD and CHF, respectively. Mean excess costs (and standard error, SE) of CAP were $14,429 (SE=44) overall. Mean excess costs by comorbidity subgroup were lowest for asthma ($13,307 (SE=123)), followed by diabetes ($21,395 (SE=171)) and COPD ($23,493 (SE=197)); mean excess costs were highest for patients with CHF ($34,436 (SE=549)). On average, indirect costs comprised 21% of total excess costs, ranging from 8% for CHF patients to 27% for COPD patients. CONCLUSIONS: Compared to patients without asthma, diabetes, COPD, or CHF, the excess cost of CAP is nearly twice as high for patients with diabetes and COPD and nearly three times as high for patients with CHF. Indirect costs made up a significant but varying portion of excess CAP costs. Returns on prevention of pneumonia would therefore be higher in adults with these comorbidities.
format Online
Article
Text
id pubmed-3585380
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35853802013-03-02 Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults Polsky, Daniel Bonafede, Machaon Suaya, Jose A BMC Health Serv Res Research Article BACKGROUND: Adults with certain comorbid conditions have a higher risk of pneumonia than the overall population. If treatment of pneumonia is more costly in certain predictable situations, this would affect the value proposition of populations for pneumonia prevention. We estimate the economic impact of community-acquired pneumonia (CAP) for adults with asthma, diabetes, chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) in a large U.S. commercially-insured working age population. METHODS: Data sources consisted of 2003 through 2007 Thomson Reuters MarketScan Commercial Claims and Encounters and Thomson Reuters Health Productivity and Management (HPM) databases. Pneumonia episodes and selected comorbidities were identified by ICD-9-CM diagnosis codes. By propensity score matching, controls were identified for pneumonia patients. Excess direct medical costs and excess productivity cost were estimated by generalized linear models (GLM). RESULTS: We identified 402,831 patients with CAP between 2003 through 2007, with 25,560, 32,677, 16,343, and 5,062 episodes occurring in patients with asthma, diabetes, COPD and CHF, respectively. Mean excess costs (and standard error, SE) of CAP were $14,429 (SE=44) overall. Mean excess costs by comorbidity subgroup were lowest for asthma ($13,307 (SE=123)), followed by diabetes ($21,395 (SE=171)) and COPD ($23,493 (SE=197)); mean excess costs were highest for patients with CHF ($34,436 (SE=549)). On average, indirect costs comprised 21% of total excess costs, ranging from 8% for CHF patients to 27% for COPD patients. CONCLUSIONS: Compared to patients without asthma, diabetes, COPD, or CHF, the excess cost of CAP is nearly twice as high for patients with diabetes and COPD and nearly three times as high for patients with CHF. Indirect costs made up a significant but varying portion of excess CAP costs. Returns on prevention of pneumonia would therefore be higher in adults with these comorbidities. BioMed Central 2012-10-31 /pmc/articles/PMC3585380/ /pubmed/23113880 http://dx.doi.org/10.1186/1472-6963-12-379 Text en Copyright ©2012 Polsky et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Polsky, Daniel
Bonafede, Machaon
Suaya, Jose A
Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults
title Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults
title_full Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults
title_fullStr Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults
title_full_unstemmed Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults
title_short Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults
title_sort comorbidities as a driver of the excess costs of community-acquired pneumonia in u.s. commercially-insured working age adults
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585380/
https://www.ncbi.nlm.nih.gov/pubmed/23113880
http://dx.doi.org/10.1186/1472-6963-12-379
work_keys_str_mv AT polskydaniel comorbiditiesasadriveroftheexcesscostsofcommunityacquiredpneumoniainuscommerciallyinsuredworkingageadults
AT bonafedemachaon comorbiditiesasadriveroftheexcesscostsofcommunityacquiredpneumoniainuscommerciallyinsuredworkingageadults
AT suayajosea comorbiditiesasadriveroftheexcesscostsofcommunityacquiredpneumoniainuscommerciallyinsuredworkingageadults